All In Biotech

Drug Trial Radar · NCT05111626

Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.

A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression

Last checked: Nov 19, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. Randomized with 515 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

515

Actual

Start

Mar 14, 2022

Primary completion

Oct 14, 2025

Study completion Oct 29, 2025

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Nov 8, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objective of Part 1 is to evaluate the safety and tolerability of bemarituzumab plus 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) and nivolumab. The main objective Part 2 is to compare efficacy of bemarituzumab plus chemotherapy (mFOLFOX6 or capecitabine combined with oxaliplatin (CAPOX)) and nivolumab to placebo plus chemotherapy (mFOLFOX6 or CAPOX) and nivolumab as assessed by overall survival.

Conditions

  • Gastric Cancer
  • Gastroesophageal Junction Adenocarcinoma

Interventions

  • BemarituzumabDrug

    Bemarituzumab will be administered as intravenous (IV) infusion.

  • NivolumabDrug

    Nivolumab will be administered as IV infusion.

  • ChemotherapyDrug

    mFOLFOX6: 5-fluorouracil, leucovorin, and oxaliplatin will be administered as IV infusion. OR CAPOX: oxaliplatin will be administered as IV infusion and capecitabine will be administered orally.

  • PlaceboOther

    Placebo will be administered as IV infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Number of Participants Who Experienced DLTsTime frame: 28 days
  2. Part 1: Number of Participants Who Experienced One or More Treatment-Emergent Adverse Events (TEAEs)Time frame: Up to 4.5 years
  3. Part 1: Number of Participants Who Experienced One or More Related TEAEsTime frame: Up to 4.5 years
  4. Part 1: Number of Participants With Clinically Significant Changes in Vital SignsTime frame: Up to 4.5 years
  5. Part 1: Number of Participants With Clinically Significant Changes in Visual AcuityTime frame: Up to 4.5 years
  6. Part 1: Number of Participants With Clinically Significant Changes in Physical ExaminationsTime frame: Up to 4.5 years
  7. Part 1: Number of Participants with Clinically Significant Changes in Clinical Laboratory TestsTime frame: Up to 4.5 years
  8. Part 2: Overall Survival in FGFR2b ≥ 10% 2+/3+ Tumor Cell Staining ParticipantsTime frame: Up to 4.5 years

Locations

348 sites in 29 countries. Site status is shown where the registry gives one.

  • Mayo Clinic - Arizona

    Phoenix, Arizona

  • The Oncology Institute Clinical Research

    Cerritos, California

  • Cancer and Blood Specialty Clinic

    Downey, California

  • City of Hope National Medical Center

    Duarte, California

  • University of California Los Angeles

    Los Angeles, California

  • University of California Irvine

    Orange, California

  • Torrance Memorial Physician Network

    Redondo Beach, California

  • Translational Research in Oncology - US Inc

    Santa Monica, California

  • Translational Research in Oncology US Inc, Trio Central Pharmacy

    Santa Monica, California

  • Olive View-University of California in Los Angeles Medical Center

    Sylmar, California

  • Presbyterian Intercommunity Hospital Health Whitter Hospital

    Whittier, California

  • Yale New Haven Hospital Yale Cancer Center

    New Haven, Connecticut

  • Florida Cancer Specialists - Fort Myers

    Fort Myers, Florida

  • Mayo Clinic

    Jacksonville, Florida

  • Adventist Health System/Sunbelt, Inc d/b/a AdventHealth Orlando

    Orlando, Florida

  • Orlando Health Cancer Institute

    Orlando, Florida

  • University of Illinois Chicago

    Chicago, Illinois

  • Greater Baltimore Medical Center

    Baltimore, Maryland

  • Henry Ford Health System

    Detroit, Michigan

  • Mayo Clinic

    Rochester, Minnesota

  • Summit Medical Group

    Florham Park, New Jersey

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Stony Brook University Medical Center

    Stony Brook, New York

  • FirstHealth Cancer Center

    Pinehurst, North Carolina

  • Gabrail Cancer Center, LLC

    Canton, Ohio

  • Providence Cancer Institute Franz Clinic

    Portland, Oregon

  • Saint Lukes University Health Network

    Allentown, Pennsylvania

  • Medical University of South Carolina

    Charleston, South Carolina

  • West Cancer Center

    Germantown, Tennessee

  • Sarah Cannon Research Institute

    Nashville, Tennessee

  • Texas Oncology Central-South

    Austin, Texas

  • University of Texas MD Anderson Cancer Center

    Houston, Texas

  • United States Oncology Regulatory Affairs Corporate Office

    The Woodlands, Texas

  • US Oncology Research Investigational Products Center

    The Woodlands, Texas

  • Virginia Oncology Associates

    Norfolk, Virginia

  • Northwest Cancer Specialists - Vancouver

    Vancouver, Washington

  • Aurora Health Care Metro Inc

    Milwaukee, Wisconsin

  • Fundacion Respirar

    Buenos Aires, Argentina

  • Hospital Italiano

    Capital Federal, Argentina

  • Sanatorio Allende

    Córdoba, Argentina

Showing 40 of 348 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.